| Nov 12 |
Tempest Therapeutics GAAP EPS of -$0.41 misses by $0.05
|
| Nov 12 |
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 12 |
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
|
| Oct 30 |
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
|
| Oct 10 |
Roche collaboration for lead asset boosts Tempest
|
| Oct 10 |
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
|
| Oct 10 |
Tempest Extends Limited Duration Stockholder Rights Plan
|
| Sep 20 |
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 18 |
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
|
| Sep 5 |
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
